Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the abortive treatment of migraines. It is a second-generation "triptan" known for its relatively rapid onset of action.
## Primary Indications
Acute treatment of migraine with or without aura in adults and pediatric patients. It is not indicated for the prophylaxis of migraines or for the treatment of cluster headaches.
## Adult Dosing
* **Initial Dose:** 5 mg or 10 mg orally (tablet or orally disintegrating tablet).
* **Dosing Interval:** If the migraine recurs after partial response, a second dose may be taken after at least 2 hours.
* **Maximum Dose:** Do not exceed 30 mg in a 24-hour period.
## Pediatric Dosing
* **Ages 6 to 17 years:**
* **Weight < 40 kg:** 5 mg as a single dose.
* **Weight ≥ 40 kg:** 10 mg as a single dose.
* **Maximum Dose:** Only one dose per 24-hour period is recommended for pediatric patients.
## Dose Adjustments
* **Patients on Propranolol:** Propranolol increases rizatriptan plasma concentrations. The maximum dose is 5 mg (limit to a maximum of 15 mg in 24 hours).
* **Renal/Hepatic Impairment:** Use caution with mild to moderate impairment; strictly contraindicated in severe hepatic or renal impairment.
## Contraindications
* History of ischemic heart disease, coronary artery vasospasm (Prinzmetal angina), or current symptoms of ischemic heart disease.
* Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathways.
* History of stroke or transient ischemic attack (TIA).
* Peripheral vascular disease.
* Ischemic bowel disease.
* Uncontrolled hypertension.
* Administration within 24 hours of another 5-HT1 agonist or ergotamine-type medication.
* Concurrent use or within 2 weeks of discontinuing a monoamine oxidase inhibitor (MAOI).
## Adverse Effects
* **Common:** Paresthesia, dizziness, somnolence, fatigue, and sensations of pressure, tightness, or pain in the chest/neck/throat.
* **Serious:** Myocardial infarction, coronary artery vasospasm, transient myocardial ischemia, arrhythmia, and serotonin syndrome (especially when combined with SSRIs/SNRIs).
## Key Drug Interactions
* **Propranolol:** Increases rizatriptan exposure (dose reduction required).
* **MAOIs:** Risk of significant hypertensive crisis or serotonin toxicity.
* **SSRIs/SNRIs:** Increased risk of serotonin syndrome; monitor clinical status.
* **Ergot-containing drugs:** Increased risk of prolonged vasospastic reactions; avoid concomitant use within 24 hours.
## Monitoring
* Monitor cardiovascular status, particularly in patients with undiagnosed cardiovascular risk factors.
* Assess for serotonin syndrome (altered mental status, autonomic instability, neuromuscular abnormalities).
## Clinical Pearls
* **Administration:** The orally disintegrating tablet (ODT) should be placed on the tongue and allowed to dissolve; it does not require water. The blister pack should be dry when opening.
* **Triptan Sensation:** Counsel patients that non-cardiac chest or neck tightness is a known transient side effect and not necessarily indicative of cardiac ischemia.
* **Medication Overuse Headache:** Frequent use (≥10 days per month) may lead to medication overuse headache; advise patients to limit use.
* **Efficacy:** If a patient fails to respond to one triptan, they may respond to a different agent within the class.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult current, reputable clinical resources (e.g., package inserts, Lexicomp, UpToDate) and local institutional guidelines before prescribing or administering medication.
